 CAMBRIDGE, Mass., Sept. 10, 2021 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic ProgramingTM platform, today announced financial results for the second quarter ended June 30, 2021. 